velaglucerase alfa

FDA Drug Profile — VPRIV

Drug Details

Generic Name
velaglucerase alfa
Brand Names
VPRIV
Application Number
BLA022575
Sponsor
Takeda Pharmaceuticals America, Inc.
NDC Codes
1
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes
INTRAVENOUS
Active Ingredients
VELAGLUCERASE ALFA

Indications and Usage

1 INDICATIONS AND USAGE VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease. ( 1 )